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Abstract: Current guidelines for the management of chronic obstructive pulmonary disease 
(COPD) recommend the regular use of inhaled bronchodilator therapy in order to relieve symptoms 
and prevent exacerbations. A variety of inhaler devices are currently available to COPD patients, 
and the choice of device is an important consideration because it can influence patients’ adherence 
to treatment, and thus potentially affect the long-term outcome. The Respimat® Soft Mist™ 
Inhaler (SMI) generates a slow-moving aerosol with a high fine particle fraction, resulting in 
deposition of a higher proportion of the dose in the lungs than pressurized metered-dose inhalers 
(pMDIs) or some dry powder inhalers (DPIs). We review clinical studies of inhaler satisfaction 
and preference comparing Respimat® SMI against other inhalers in COPD patients. Using 
objective and validated patient satisfaction instruments, Respimat® SMI was consistently shown 
to be well accepted by COPD patients, largely due to its inhalation and handling characteristics. 
In comparative studies with pMDIs, the patient total satisfaction score with Respimat® SMI was 
statistically and clinically significantly higher than with the pMDI. In comparative studies with 
DPIs, the total satisfaction score was statistically significantly higher than for the Turbuhaler® 
DPI, but only the performance domain of satisfaction was clinically significantly higher for 
Respimat® SMI. Whether the observed higher levels of patient satisfaction reported with 
Respimat® SMI might be expected to result in improved adherence to therapy and thus provide 
benefits consistent with those recently shown to be associated with sustained bronchodilator 
treatment in patients with COPD remains to be proven.
Keywords: Respimat® Soft Mist™ Inhaler, pressurized metered-dose inhalers, pressurized 
metered-dose inhalers, inhaler devices
Introduction: inhalation therapy in COPD
Chronic obstructive pulmonary disease (COPD) poses many therapeutic challenges, 
both for patients and their physicians. Unlike asthma, COPD is not fully reversible 
and causes a progressive deterioration in lung function over time. Furthermore, the 
underlying inflammatory process in COPD differs from that in asthma and is less 
susceptible to treatment with inhaled corticosteroids.1,2 Hence, current pharmacological 
management of COPD, as recommended in treatment guidelines such as those of the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD)3 focuses primarily on 
achieving sustained bronchodilation in order to relieve symptoms by decreasing both 
airway obstruction and pulmonary hyperinflation. These recommendations are based 
on a substantial body of evidence showing that regular treatment with long-acting 
bronchodilators relieves symptoms and reduces exacerbations in symptomatic 
patients with COPD.3,4 In addition, recent data from large clinical trials in COPD International Journal of COPD 2009:4 382
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suggest that sustained bronchodilation with both long-acting 
anticholinergic and beta2-adrenergic bronchodilators is 
associated with a reduced loss of lung function over time,5–8 
an improvement in quality of life5–8 and possibly reduced 
mortality.6,7
A variety of inhaler devices are available for bronchodilator 
treatment in COPD patients, including pressurized metered-
dose inhalers (pMDIs), dry powder inhalers (DPIs), and 
nebulizers.9 Each of these devices has its own advantages 
and disadvantages: pMDIs are convenient and relatively 
inexpensive, but many patients find it difficult to use them cor-
rectly, often because of problems in coordinating actuation or 
inhaling too quickly.9,10 Furthermore, poor inhaler technique 
has been shown in asthma patients to result in suboptimal 
treatment and outcomes.11,12 DPIs are breath-actuated, 
so coordination of actuation and inhalation is not necessary, 
but many patients are unable to use these devices correctly9,13 
and delivery to the lungs may be decreased if, for example, 
inhalation is too slow or if the time to peak inspiratory flow 
is too long.9 Nebulizers are generally bulky and inconvenient, 
can be expensive, and require regular maintenance and 
long treatment times, and hence tend to be used mainly by 
less mobile patients.9 Given the relative advantages and 
disadvantages of each device type, the choice of inhaler for 
COPD treatment in an individual patient will require careful 
consideration of the patient’s specific needs and preferences 
as well as the patient’s inhaler technique.11,14
A number of factors may influence COPD patients’ 
attitudes to inhaled therapy and their preferences for a 
specific device (Table 1).15–17 These include disease-related 
issues such as the perceived efficacy of treatment in the 
face of a progressive decline in lung function, an aversion 
to or concerns about regular medication use, concern about 
drug side effects, and device-related issues such as the 
convenience, ease of use of the device, cost, perceived device 
efficacy and physician device preference. It is not possible 
to predict which factors will have the greatest influence on 
adherence to inhaled therapy, as this will vary from patient to 
patient. However in practice, perceived efficacy of therapy is 
likely to have a strong influence on inhaler adherence.
The choice of inhaler for a particular patient is an 
important issue in COPD because of the importance of 
adherence to therapy, which is likely to be influenced by 
patients’ attitudes to the device and their experiences in using 
it. If the patient feels a therapy is not working, adherence is 
likely to be low, but poor efficacy could also be caused by the 
inhaler technique being incorrect for the device being used. 
This may potentially affect the outcome of treatment,18,19 
as reflected in the observation by a former USA Surgeon 
General that “Drugs don’t work if patients don’t take them”.20 
The issue is controversial however, as two large systematic 
reviews of the clinical inhaler literature have concluded that 
there is no strong evidence that the type of inhaler device 
used has any affect on clinical outcome in patients with 
asthma and COPD.21,22 However, there are important caveats 
that must be considered before accepting these analyzes at 
face value. The vast majority of the clinical studies reviewed 
in these analyzes compared inhalers in licensing studies, 
which are usually designed and powered to show equivalence 
and have often tested doses of drugs that are at the top of 
their respective dose–response curves, where response is 
insensitive to changes in dose. Furthermore, these studies 
use highly selected patients with excellent inhaler technique 
who not only consent to participate, but also receive special 
care consisting of regular, reinforcing contact with healthcare 
professionals, a feature that emphasizes adherence to therapy. 
The indications from real-life studies in asthma are that 
inhalers do make a difference to disease control outcomes,23,24 
Table 1 Factors affecting patients’ attitudes to COPD therapy and 
their preferences for a specific inhaler device12–17
Disease and drug factors
  Progressive nature of COPD (declining benefit)
  Concerns about regular medication, including side effects
  Potential side-effects of treatment
  Perceived drug efficacy (symptom relief/prevention of exacerbations)
Device factors
  Perceived device efficacy
  ease of use of device
    •  Need for actuation/inhalation coordination
    •  Ability to actuate device (strength, arthritis issues)
    •  Ability to generate sufficient inspiratory flows (dry powder inhalers)
  Convenience of device
    •  Dose and refill frequency
    •  Dose counter
    •  Availability of combination inhalers
  Feelings of stigmatization due to need for device use in public
  Physician device preference
  Availability of drug/device preparations
  “Brand loyalty”
  Cost
  Time to learn; clear instructions
  Size, weight, taste, device appearance
  Cleaning issues
  Disposability/environmental issuesInternational Journal of COPD 2009:4 383
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but studies of similar design have not yet been done in COPD 
patients. The American College of Chest Physicians and 
the American College of Asthma, Allergy and Immunology 
(ACCP/ACAAI) have also recently concluded that all of the 
marketed inhalation devices can work equally well, provided 
that patients can and will use the devices as prescribed.22 The 
guidelines committee acknowledged the limitations of this 
type of analysis, which for the most part was dependent on 
industry-sponsored comparative studies which were designed 
to show device equivalence in highly selected and trained 
groups of patients, under non-real life conditions. Importantly, 
most such trials have not attempted to use validated device 
satisfaction or preference assessment tools.
Notwithstanding these uncertainties, it is clear that in 
surveys of healthcare professionals, ease of use and patient 
preference for device are regarded as the most important 
considerations when selecting an inhaler for patients.25,26 
Furthermore, it is also clear that not all patients can use all 
inhalers equally well. Patients clearly vary in their preferences 
for different inhalers27,28 and frequently do not see devices as 
being interchangeable.
Although relatively few studies have specifically examined 
adherence to therapy in COPD patients, the available evidence 
suggests that (as in other chronic diseases) adherence is 
poor.19,29 For example, in the Lung Health Study, almost 70% 
of participants reported “satisfactory” or better compliance 
at 4 months, but only 48% were classified as showing this 
level of adherence at 1 year.30 Similarly, a cohort study in the 
USA found that approximately 60% of elderly patients (aged 
65 years and older) with moderate or severe COPD were 
poorly adherent to inhaled corticosteroid therapy.31 There 
is good evidence that in asthma patients, poor adherence to 
therapy is associated with worse outcomes,32–34 and the limited 
evidence available suggests that this is also true in COPD. 
For example, in the US cohort study described above, better 
adherence was associated with a 20% decrease in the number 
of hospital visits over one year.31 Similarly, in a study involving 
82 COPD patients who were receiving home nebulizer therapy, 
46 patients (56%) were found to be poorly adherent and this 
trait was associated with impaired quality of life.35 Thus, it does 
appear that in real life conditions, choice of inhaler device can 
have an impact on disease control, and that the patient–device 
interface is crucial. Therefore, there is clearly scope for 
improving adherence to inhalation therapy in COPD.
Soft mist inhalers (SMIs) represent a new development 
in inhaled bronchodilator therapy in COPD.9 These 
are propellant-free, multiple-dose devices that use liquid 
formulations similar to those in nebulizers. Currently, the only 
SMI in clinical use for the treatment of COPD is the 
Respimat® Soft Mist™ Inhaler (Respimat® SMI; Boehringer 
Ingelheim, Ingelheim, Germany). The Respimat® SMI uses 
the energy of a compressed spring to generate an aerosol over 
a period of about one second with a high fine particle fraction 
and with a velocity approximately one-tenth of that generated 
by chlorofluorocarbon-based pMDIs (CFC-pMDIs).36 
Scintigraphic studies have shown that as a result of these 
device and aerosol characteristics, oropharyngeal deposition 
is reduced and lung deposition with Respimat® SMI is several 
times greater than with CFC-pMDIs and the Turbuhaler® 
DPI.37,38 Because of this, smaller nominal doses of drug 
can be used in COPD patients,39 and Respimat® SMI can 
increase lung deposition even in COPD patients with poor 
inhaler technique.40
This paper reviews the available data on patient preferences 
from clinical studies with the Respimat® SMI in COPD 
patients, including a discussion of the instruments available 
for measuring patient satisfaction with inhalers. Data from 
both comparative and non-comparative studies with Respimat® 
SMI are reviewed. In three comparative studies, patients used 
Respimat® SMI and the comparator device, but because masking 
of the devices being compared was not feasible, patients and 
investigators knew the identity of the two test devices. Two of 
these trials used double-dummy trial designs.
Measurement of patient satisfaction 
and preference with inhaler devices
Patient satisfaction and preference with inhaler devices have 
attracted increasing attention in recent years, because of the 
potential impact that patients’ experiences with their inhalers 
might have on adherence to therapy and hence long-term 
outcome.16,18,41 Inhaler preference is now recognized as a 
valid patient-reported outcome, and although the science 
of studying satisfaction or preference with medication or a 
device is relatively new, the basic principles are clear.42 Until 
recently, however, these measurement principles have not 
penetrated widely into the design of inhaler satisfaction and 
preference trials, and standards for measuring and reporting 
patient satisfaction and preferences have varied widely 
between studies.16,17 The types of instruments commonly used 
in inhaler satisfaction and preference studies to date have 
ranged from a simple preference question to non-validated 
proprietary questionnaires. Response scales used have varied 
from open-ended questions, through poorly-defined response 
scales, to visual analogue and Likert scales. Furthermore, 
most questionnaires have been developed without input 
from patients or experts in psychometric testing. This lack of International Journal of COPD 2009:4 384
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precision with measurement has made the device preference 
literature difficult to interpret.
In designing a rigorous inhaler satisfaction/preference 
trial, the single most important factor is the use of a reliable 
and valid inhaler satisfaction/preference measurement tool16,17 
and such instruments have only recently become available.43,44 
In a recent review of 30 published inhaler preference studies, 
only 2 studies were found to have used robust instruments for 
measuring preference and satisfaction.16 The 2 instruments 
in question, the Patient Device Experience Assessment 
(PDEA)43 and the Patient Satisfaction and Preference 
Questionnaire (PASAPQ),44 were developed by experts in 
psychometric testing and subjected to field testing. Of these, 
only the PASAPQ has a published validation.44 The PASAPQ 
(Table 2) is a self-administered 15-item instrument that 
includes 13 satisfaction items, a preference item, and a question 
on willingness to continue using the device. Details on the 
development and use of the PASAPQ have been published44,45 
and included obtaining input from patients and clinical 
experts, using quantitative and qualitative analyses to select 
among the items, and psychometric testing in clinical studies 
applying techniques commonly used in the development 
of patient reported outcome measures. It was developed 
without regard for a particular device or treatment in order 
to be widely applicable to respiratory treatments. In part 1 
of the PASAPQ, patients rate each of the 13 satisfaction 
items using a 7-point Likert scale (1 = very dissatisfied and 
7 = very satisfied), as well as answer a global satisfaction 
question. In part 2, patients answer global questions on inhaler 
preference and on willingness to continue using the device. 
The PASAPQ has been shown to be reliable and responsive 
in discriminating between preferred and non-preferred 
devices in patients with COPD and asthma.44 Validation 
of the PASAPQ included a determination of the minimum 
important difference (MID) between devices, allowing an 
assessment of the clinical significance of differences observed 
in testing. The MID was estimated using both anchor-based 
and distributional approaches, and although a difference of 
3 or 4 points was found to be sufficient to achieve a small 
effect, most MID estimates were in the 8- to 10-point range. 
For this reason, a 10-point difference between devices for 
the Performance, Convenience and Total Satisfaction scores 
has been recommended as a conservative indication of a 
difference that is meaningful to patients.44,45
Respimat® SMI: ease-of-use studies
Ease-of-use studies for the Respimat® SMI have been 
conducted in patients naïve to the device and have mainly 
employed simple, non-validated, questionnaires which were 
nevertheless specific to the Respimat® SMI. Results from 
Table 2 Items and scoring for the patient satisfaction and preference questionnaire (PASAPQ)44,45
Domain Question Description Scoring
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Q6 Instructions for use 4 = Neither satisfied nor dissatisfied
Q7 Size of inhaler 5 = Somewhat satisfied
Q8 Durability of inhaler 6 = Satisfied
Q9 ease of cleaning inhaler 7 =   Very satisfied
Q12 ease of holding during use
Q13 Convenience of carrying
Stand alone 
questions
Q14 Overall satisfaction
Preference
 Prefer inhaler 1 
 Prefer Inhaler 2 
 No preference
Willingness to continue
each inhaler given a score between  
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several non-comparative studies with the Respimat® SMI 
delivering placebo, ipratropium or ipratropium/fenoterol are 
shown in Table 3. The majority of participants in these studies 
found the device easy to use regardless of patient age and felt 
confident in using the device after 1 day of use.
Ease of use was also assessed during a trial comparing 
Respimat® SMI and a hydrofluoroalkane (HFA) pMDI 
(Boehringer Ingelheim study number 215.1357).27 The 
majority of patients (96% to 98%) were able to achieve 
satisfactory technique within five attempts with each device 
and slightly more patients were judged to have retained good 
technique after 7 weeks with Respimat® SMI than with the 
HFA-pMDI (96.9% and 93.8%, respectively).
Respimat® SMI: satisfaction  
and preference studies
Satisfaction and preference assessments have been 
incorporated into various trials of Respimat® SMI and these 
are summarized in Tables 3 and 4. In most of the trials, the 
device was used to deliver bronchodilators, usually ipratropium 
bromide plus fenoterol. In two of the three comparative trials, 
the inhalers being compared contained the same active drug 
substance. Patient satisfaction with Respimat® SMI was also 
assessed using post hoc questionnaires at the end of treatment 
in subsets of COPD patients (n = 47 and 129, respectively) in 
the two clinical trials from Germany (Boehringer Ingelheim 
244.2484) and Canada (Boehringer Ingelheim 215.1349). 
In the German trial, patients aged 37 to 87 years received either 
ipratropium bromide plus fenoterol (Berodual®) or placebo 
once daily for 12 weeks; in the Canadian trial, patients aged 
19 to 88 years received ipratropium bromide or placebo once 
daily for 6 months. All patients in the German study and 92% 
of those in the Canadian study had previously used a pMDI. 
In both studies, patients were asked to rate their satisfaction 
with Respimat® SMI on a scale of 1 to 10, where 1 indicated 
“extremely dissatisfied” and 10 indicated “extremely 
satisfied.” Ratings of 9 or 10 were given by 74% of patients 
in the Canadian study and 64% of those in the German study. 
The most commonly reported reasons for satisfaction with 
Respimat® SMI were inhalation characteristics (eg, the feeling 
of a better effect than with a pMDI), or features relating to 
handling of the device (eg, ease and convenience of use), and 
a high proportion of patients (80% and 72% in the Canadian 
and German studies, respectively) said they were “extremely 
interested” in continuing with Respimat® SMI rather than 
their current inhalers.
In an observational cohort study in Germany (Boehringer 
Ingelheim 215.1362), 4602 patients with asthma, COPD 
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or both, were interviewed 4 weeks after starting a new 
prescription of ipratropium bromide plus fenoterol via Respi-
mat® SMI.46 On a 5-point scale from “unsatisfactory” to “very 
good”, ratings of “good” or “very good” were given by 88.7% 
of patients for handling of Respimat® SMI and 93% for how 
easy it was to inhale from the device. Therapy with Respimat® 
SMI was rated better or much better than therapy with the 
patient’s previous inhaler by 81% of patients, and 94.4% 
actually continued using Respimat® SMI.46 In a further study 
(Boehringer Ingelheim study number 215.1363), 2006 patients 
with asthma, COPD, or both received ipratropium bromide 
plus fenoterol via Respimat® SMI for 12 weeks, and patient 
and physician satisfaction with the device were assessed by 
questionnaire after 4, 8, and 12 weeks’ treatment.47 At 4 weeks, 
1431 (71.3%) patients reported that they were “satisfied” or 
“very satisfied” with Respimat® SMI and this number grew 
to 1731 (86.3%) after 12 weeks of treatment. At the end of 
the study, the majority of physicians and patients preferred 
Respimat® SMI to their previous therapy.47
In 3 trials that have compared Respimat® SMI with other 
devices, patients’ comparative satisfaction and preference 
for the devices were assessed with the validated PASAPQ 
instrument and the results of these trials are discussed 
below.27,48,49
Comparison with pMDIs
Patient preferences for Respimat® SMI and a HFA pMDI 
were compared as the primary endpoint in a non-blinded 
randomized crossover trial in patients with asthma, COPD, 
or both (Boehringer Ingelheim study number 215.1357).27 
Patients received equivalent doses of ipratropium bromide 
plus fenoterol via each device for 7 weeks, and satisfaction 
and preference were assessed using the PASAPQ at the end 
of each treatment period. Of 224 patients analyzed, 72.3% 
preferred Respimat® SMI and 17.4% preferred the HFA pMDI 
(P  0.001) (Figure 1a). This preference was unaffected by 
age or the presence of disorders that might have adversely 
affected inhaler handling. Mean satisfaction scores in the 
convenience domain were very similar for the 2 devices, but 
Respimat® SMI scored significantly better than the HFA pMDI 
in the performance domain, resulting in significantly higher 
total PASAPQ scores (Table 4).27 Mean total satisfaction 
score differences of 10.8 points on the PASAPQ indicated 
that the Respimat® SMI met the pre-determined MID for a 
clinically meaningful difference between devices.44 At the end 
of the study, the median scores for willingness to continue 
using the device were 85 for Respimat® SMI and 50 for the 
HFA pMDI, on a scale of 0 to 100 where 0 = “not willing” International Journal of COPD 2009:4 387
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satisfaction score for Respimat® SMI than for Turbuhaler® 
that met or exceeded the MID for the PASAPQ, whereas 
no patients gave a score for Turbuhaler® that exceeded the 
Respimat® SMI score by this threshold. The proportion of 
patients who preferred Respimat® SMI was 73.7%, with 
17.1% preferring the Turbuhaler® and 9.2% expressing no 
preference for either device (Figure 1b). Patients’ willingness 
to continue using the device was higher for Respimat® SMI 
than for Turbuhaler® (mean scores of 80 and 62, respectively, 
P  0.0001).48
A second study that used the PASAPQ to compare sat-
isfaction and preference with a DPI (Boehringer Ingelheim 
study number 215.1366) was conducted in 150 patients 
with COPD or asthma who added ipratropium bromide plus 
fenoterol in Respimat® SMI to their existing Diskus®-based 
therapy (usually corticosteroid plus long-acting beta-agonist) 
for 4 weeks.49 At the end of the study, the mean total PASAPQ 
score was statistically, but not clinically significantly higher 
with Respimat® SMI than with Diskus® (Table 4), as were the 
mean scores for the two PASAPQ domains of performance and 
convenience (Figure 2b). Overall, 63.5% of patients expressed 
a preference for Respimat® SMI, 33.8% for Diskus® and 2.7% 
expressed no preference for either device (Figure 1c).
Conclusions
Inhaled bronchodilator therapy has a central place in the 
management of COPD, but the choice of the most appropriate 
and 100  = “definitely willing” (P  0.001 for median 
difference). Clinical efficacy in this trial was assessed using 
daily diary cards which recorded evening peak expiratory 
flow rates, rescue medication use and daytime and nighttime 
symptom scores. The fact that no significant differences in 
clinical efficacy were observed between devices strengthens 
the observed differences in device satisfaction that favored 
Respimat® SMI in this trial.27
Comparisons with DPIs
Patients’ preferences for Respimat® SMI and the Turbuhaler® 
DPI were compared in a randomized, controlled study 
(Boehringer Ingelheim study number 1047.16) involving 
153 patients (mean age 41 years) with moderate or severe 
asthma.48 Patients received the inhaled corticosteroid 
budesonide via one of the devices (randomly allocated) and 
placebo via the other in a double-dummy design for 12 weeks, 
and satisfaction was assessed by means of the PASAPQ at the 
end of the study. Total satisfaction scores for Respimat® SMI 
were significantly higher than for Turbuhaler® (difference 
8.6, Table 4), as were those in the performance domain 
(difference 15.1, Figure 2a). For the population studied as 
a whole, this difference in the performance score exceeded 
the recommended MID. Although statistically significant, 
the observed total satisfaction score difference in favor 
of the Respimat® SMI (8.6) did not meet the MID criterion 
of 10. However, 60 patients (39.2%) did give a higher total 
C) vs Diskus®
63.5%
33.8%
2.7%
Preferred Respimat ® SMI 
No preference for either 
device, or no reply 
Preferred other inhaler
A) vs pMDI
72.3%
17.4%
10.3%
B) vs Turbuhaler
®
73.7%
17.1%
9.2%
Figure 1 Proportion of patients indicating preference for respimat® Soft MistTM Inhaler (SMI) or an alternative inhaler device in 3 studies that used the Patient Satisfaction 
and Preference Questionnaire (PASAPQ):  A) Pressurized metered-dose inhaler (pMDI) in a clinical study (n = 224);27 B) Turbuhaler® in a clinical study (n = 153);48 C) Diskus® 
in an observational study (n = 150).49International Journal of COPD 2009:4 388
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inhaler for a given patient is often not straightforward. 
The ease of use and performance characteristics of the 
inhaler will markedly influence patients’ acceptance of the 
device, as will the patients’ attitudes to their illness and 
chronic medication use in general. Clinicians, and patients 
with lung disease must choose the most appropriate inhaler 
for their needs from a vast and growing array of efficient 
devices. Implicit in selecting an inhaler is the as yet unproven 
(although widely accepted) assumption that patient preference 
for a device will promote better adherence with therapy, which 
will in turn lead to improved disease outcome. Although it 
has been difficult to demonstrate that this time-honoured 
preference-adherence-outcome paradigm is true, it does 
appear that in real life conditions, choice of inhaler device can 
have an impact on disease control, and that the patient/device 
interface is crucial for both asthma12,23,50,51 and COPD, where it 
has been shown that device adherence affects outcomes such 
as the frequency of exacerbations and hospitalizations.31,35
Studies with the Respimat® SMI have consistently shown 
that this device is well accepted by patients, and that patient total 
satisfaction with this device is higher than for the pMDI. Patient 
perception of the performance of the Respimat® SMI is also 
higher compared to the Turbuhaler® DPI. Importantly, many 
of these studies have used a robust and validated instrument 
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(the PASAPQ) to measure patient satisfaction/preference. It is 
notable that the findings in patients participating in randomized 
clinical trials, whose ability to use inhalers is usually better 
than in day-to-day practice, have been confirmed by the find-
ings of observational studies of Respimat® SMI in a primary 
care setting. The findings also seem to apply equally well to 
patients with COPD and asthma, despite differences between 
these patient groups in attitudes to disease and medication that 
might influence the basis for satisfaction and preference.15
A possible drawback when interpreting satisfaction and 
preference findings from studies that use active treatment arms 
is whether the medication inhaled from the device biases the 
patient’s opinion of the device. The use of the PASAPQ helps 
to reduce bias because the questions in it were designed to be 
specific to attributes of the inhaler and, as it is self-administered, 
assessor bias is avoided. Bias can also be minimized by using 
a double-dummy design to help obviate the fact that patients 
cannot be blinded to inhalers that look and function differently. 
Such an approach was followed in two of the comparative trials 
described above. Bias may also be reduced by comparing the 
effect of a single drug treatment via two different inhalers, as 
was done in the Respimat® SMI vs Turbuhaler® comparison and 
the Respimat® vs pMDI crossover study.27,48 In the Respimat® 
SMI vsDiskus® comparison,49 patients were comparing an 
anticholinergic plus short-acting beta-agonist via Respimat® 
SMI with, in most cases, a corticosteroid plus long-acting 
beta-agonist combination via Diskus®, so differences in 
bronchodilator efficacy, speed of onset and tolerability might 
have affected patients’ satisfaction ratings.
The observed high patient preferences for Respimat® SMI 
over other devices might be expected to result in improved 
adherence to therapy and perhaps outcome, but this still 
needs to be tested prospectively, ideally in “real-life” settings 
using randomized controlled trials with broad inclusion 
criteria. Persistence with therapy is particularly important 
in COPD, because sustained adherence to bronchodilator 
therapy has been shown to slow the progressive decline in 
lung function5–8,52 and may possibly reduce mortality from this 
disabling disease.6,7 An inhaler such as the Respimat® SMI that 
is convenient to use, reliable, and well accepted by patients 
should offer advantages in this respect during long-term 
treatment. Such a device might be particularly appropriate in 
patients who are new to inhaled therapy, as it could offer the 
opportunity to establish a pattern of long-term adherence.
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